Prothena Corporation PLC (PRTA) Stake Lessened by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP reduced its stake in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 8.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 623,489 shares of the biotechnology company’s stock after selling 60,671 shares during the quarter. Westfield Capital Management Co. LP owned approximately 1.62% of Prothena worth $40,383,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of PRTA. Bank of Montreal Can boosted its stake in shares of Prothena by 6.7% during the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 117 shares during the period. Quantbot Technologies LP boosted its stake in shares of Prothena by 672.7% during the second quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,628 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Prothena by 187.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 1,549 shares during the period. Strs Ohio boosted its stake in shares of Prothena by 69.2% during the third quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 900 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Prothena by 8.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,249 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 250 shares during the period.

A number of analysts have recently issued reports on PRTA shares. Wedbush lowered shares of Prothena from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $75.00 to $55.00 in a research note on Monday, November 20th. Oppenheimer reissued a “buy” rating and set a $70.00 target price on shares of Prothena in a research note on Thursday, November 9th. Deutsche Bank set a $73.00 target price on shares of Prothena and gave the company a “buy” rating in a research note on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $79.00 target price on shares of Prothena in a research note on Thursday, September 28th. Finally, ValuEngine lowered shares of Prothena from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $76.75.

In related news, insider Tara Nickerson sold 17,500 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the sale, the insider now directly owns 19,500 shares of the company’s stock, valued at $1,240,200. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gene G. Kinney sold 2,800 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $70.00, for a total transaction of $196,000.00. Following the completion of the sale, the insider now directly owns 5,593 shares of the company’s stock, valued at $391,510. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,424 shares of company stock valued at $1,922,787. 3.10% of the stock is owned by insiders.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at $47.32 on Monday. Prothena Corporation PLC has a one year low of $44.03 and a one year high of $70.00.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.04. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.28 million. During the same period in the prior year, the firm earned ($1.26) earnings per share. The firm’s revenue for the quarter was down 33.6% compared to the same quarter last year. analysts anticipate that Prothena Corporation PLC will post -4.27 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Prothena Corporation PLC (PRTA) Stake Lessened by Westfield Capital Management Co. LP” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/12/04/prothena-corporation-plc-prta-stake-lessened-by-westfield-capital-management-co-lp.html.

Prothena Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

What are top analysts saying about Prothena Corporation PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Prothena Corporation PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit